Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Merck
AstraZeneca
Express Scripts
Dow

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Prexasertib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 14 clinical trials for Prexasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Neoplasms, Head and Neck Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and St. Jude Children's Research Hospital.

There are three US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for Prexasertib
TitleSponsorPhase
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaMemorial Sloan Kettering Cancer CenterPhase 1/Phase 2
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsEli Lilly and CompanyPhase 1
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research HospitalPhase 1

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib   Start Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN)   Start Trial
Prexasertib   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
Prexasertib   Start Trial 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Prexasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Prexasertib Argentina 106772 2035-12-07   Start Trial
Prexasertib Australia 2016367041 2035-12-07   Start Trial
Prexasertib Brazil 112018008398 2035-12-07   Start Trial
Prexasertib Canada 3003914 2035-12-07   Start Trial
Prexasertib Chile 2018001432 2035-12-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Merck
Medtronic
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.